Clinical studies under way
Working with patients and doctors to develop new treatment options to control this disease.
NeuroVia’s lead drug candidate, NV1205, is being developed for the treatment of X-linked Adrenoleukodystrophy (X-ALD). NV1205 is an orally administered clinical-stage drug candidate that was shown to be safe and well-tolerated in Phase 1 clinical studies.
NeuroVia has initiated the PEDALS trial, a Phase 1/2 interventional study in childhood cerebral ALD patients. In addition, a NeuroVia is conducting the SADDLE trial, an observational study for male children with X-ALD.
September 28, 2017
NeuroVia Appoints Daniel Bradbury and Edward Kaye to its Board of Directors